Zim Laboratories Limited has informed the Exchange about Investor Presentation

ZIM LABORATORIES LIMITED __________________________________________________________________________________________ www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172 Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470 Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960 Ref No.: ZLL/CS/BM/BSE-NSE Date : 07.08.2025 BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400 National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB) Dear Sir, Sub : Q1 FY26 - Earnings Presentation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed Q1 FY26 - Earnings Presentation. Kindly take the intimation on record. Thanking you, Yours faithfully, For ZIM LABORATORIES LIMITED (Piyush Nikhade) Company Secretary and Compliance Officer Membership No. A38972 Encl : As above. PIYUSH SIDDHESHWAR NIKHADEDigitally signed by PIYUSH SIDDHESHWAR NIKHADE DN: c=IN, postalCode=440012, st=MAHARASHTRA, street=325 MAHALAXMI APPT NAGPURDHANTOLIWEST CENTREL ROAD 440012, l=NAGPUR, o=Personal, title=3526, serialNumber=3cced6ca26d23668ee558b723602e5236d527adc99269a3746951cdb919fca04, pseudonym=352620221206180703459, 2.5.4.20=42e9b6a98356f9095ec25716fc30d8cb8463fc1dc23adada5293c43849baaf78, email=CSPIYUSHNIKHADE@GMAIL.COM, cn=PIYUSH SIDDHESHWAR NIKHADE Date: 2025.08.07 19:41:59 +05'30'ZIM LABORATORIES LIMITEDEARNINGS PRESENTATIONwww.zimlab.inQ1FY26 SAFE HARBOURThe presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. By accessing this presentation, you are agreeing to be bound by the trading restrictions.The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its affiliates, advisors or representatives are under an obligation to update, revise or affirm.Certain statements contained in this presentation may be statements of the Company’s beliefs, plans and expectations about the future and other forward-looking statements. The forward-looking statements are based on management’s current expectations or beliefs as well as a number of assumptions about the Company’s operations and facto beyond the Company’s control or third-party sources and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward looking statements, which speak only as of the date of this presentation.The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. You acknowledge and agree that the Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.2CONTENT301Q1FY26 HIGHLIGHTS02FINANCIAL PERFORMANCE – Q1FY2603BUSINESS MIX04R&D & INNOVATION05SHAREHOLDING41 NIP filing done in EU; 4 NIP and 10 ODS filings done in RoW & Pharmerging markets during the quarter while 3 ODS MA’s receivedFinancial HighlightsBusiness HighlightsDossier outlicensing fees of ₹ 45 Mn in Q1FY26 as milestone paymentsTotal Operating Income at ₹718 Mn, down 12.3% YoY from ₹818 Mn in Q1FY25EBITDA is at ₹57 Mn, down 36.7% YoY from ₹90 Mn in Q1FY25; margins at 7.9% from 11%₹53 Mn invested in Capex including ₹23 Mn towards BE studies and regulatory filingsTotal R&D spend was at ₹79 Mn, accounting for 11% of the Total Operating IncomeWe received 2 MA’s for Dutasteride Tamsulosin & Rizatriptan Benzoate Oral Films through our subsidiary in AustraliaWe completed onboarding of our BD team with regional heads in place for Africa, CIS , LatAm, MENA and SE AsiaQ1FY26 HIGHLIGHTSFINANCIAL PERFORMANCE – Q1FY265818718Q1FY25Q1FY26Q1FY25Q1FY26Total Operating Income9057Q1FY25Q1FY26Q1FY25Q1FY26EBITDA & EBITDA margin11 %1.1 %Profit After Tax (PAT) & PAT marginoTotal Operating Income stood at ₹ 718 Mn primarily due to inability to supply to our legacy clients owing to geo-political issues in key markets of Middle East and Bangladesh oEBITDA was at ₹57 Mn and margin was at 7.9%, degrowth of 36.7% owing to reduction in toplineoPAT was negative at (₹19 Mn) on account of lower topline and increased depreciation and finance costs9-19Q1FY25Q1FY26Q1FY25Q1FY267.9%-2.6%BUSINESS MIX6oQ1FY26 : Pharma business contributed to 78% of revenue while Nutra contributed 22% in line with past trends of business mix oNutra Revenue contribution drop YoY was due to decrease in Nutra PFI business particularly in MENA region due to geo- political instability thus causing discontinuity in supplies to those regionsPharma Revenue (₹ Mn) & Contribution to Total Operating Income (%)Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%)26626822419615733%29%23%18%22%Q1FY25Q2FY25Q3FY25Q4FY25Q1FY2655265473989156067%71%77%82%78%Q1FY25Q2FY25Q3FY25Q4FY25Q1FY267REVENUE MIXoQ1FY26: Revenue from exports decreased 15.2% YoY to ₹602 Mn, compared to ₹709 Mn in Q1FY25 oIndia Business grew 30.2% to ₹100 Mn in Q1FY26 owing to increase in high value institutional businessoDecrease in exports resulted from a combination of reduction in Innovative product contribution to topline and supply difficulties in MENA due to geo-political instability709, 87%77, 9%32, 4%602, 84%100, 14%16, 2%Q1FY25Q1FY262,870, 78%646, 18%158, 4%3,125, 83%536, 14%130, 3%FY24FY25Export India Deemed ExportNumbers in ₹MnINNOVATIVE PRODUCT CONTRIBUTION8109821121781641351474612.7%8.5%9.5%21.8%17.8%14.0%13.5%6.3%Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26(NIP + OTF) Revenue (₹ Mn) & Contribution to Operating Income (%)oQ1FY26: NIP + OTF operating income contribution declined to ₹46 Mn and a contribution of 6.3%; NIP was ₹12 Mn & OTF was ₹34 Mn for Q1FY26; contribution to total operating income was 12.9% including licensing feesoAgreements for Innovative Products across regions resulted in ₹45 Mn from dossier licensing milestone payments vs ₹4 Mn in Q1FY25License fees of ₹45 Mn in Q1FY26 vs ₹4 Mn in Q1FY25ProductTherapy AreaMarket ReviewFormulation DevelopmentValidationBE StudiesRegulatory FilingRegulatory ApprovalsCommercial SuppliesProduct 1Urology Product 2GastrointestinalProduct 3Anti – CoagulantDi-Methyl FumarateCNSProduct 5UrologyProduct 6 Rheumatoid ArthritisAzithromycin SuspensionAnti - InfectiveProduct 8 AnalgesicProduct 9GastrointestinalProduct 10GastrointestinalProduct 11Skin Disorders (Anti psoriatic) Product 12Urology9ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK)ProductTherapy AreaMarket ReviewFormulation DevelopmentValidationBE StudiesRegulatory FilingRegulatory ApprovalsCommercial SuppliesRizatriptanCNSSildenafilErectile DysfunctionProduct 3CNSProduct 4Erectile DysfunctionBuprenorphine Opioid De Addiction10ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK)R&D DRIVING PRODUCT INNOVATION1190276R&D TeamSizePhDsPost- GraduatesR&D Expense Mix % of Total R&D Investment and Total R&D Investment as % of Total Operating Income 84₹79 MnNIP Filed in the EU to dateVersatile Technology PlatformsAllocated in Q1FY26 on Opex, Facility, BE Studies, Registrations, etc.oQ1FY26: ₹19 Mn allocated for BE studies and registrations, for advancing the Innovative Products (NIP + OTF) pipelineoProgress in NIP development and filings, with 8 products developed and filed in EU oTotal of ₹79 Mn in R&D allocation focused on product development, dossier upgrades and infrastructure56%64%1%12%43%24%Q1FY25Q1FY26Capital Expenses on BE study,registrations etcCapital Expenses onInfrastructure & EquipmentR&D Expenses in P&L(Employee; Material,BE-Studyetc.)11%9.8%INCOME STATEMENT12Particulars (₹ Mn)Q1FY26Q1FY25YoY%FY25FY24YoY%Total Operating Income718818(12.3%)3,7903,6743.2%Other Income151050%585213%Total Income733828(11.6%)3,8483,7253.3%EBITDA5790(36.7%)4954656.4%EBITDA %7.9%11%(310bps)13.1%12.7%40bpsFinance Cost332913.8%11469(65.2%)Depreciation4849(2%)20116025.6%Profit Before Tax (PBT)(24)12(300%)180236(23.8%)PBT %(3.3%)1.5%(480bps)4.8%6.4%(170bps)Profit After Tax (PAT)(19)9(308.8%)122172(29.3%)PAT %(2.6%)1.1%(370bps)3.2%4.7%(150bps)EPS (₹ / Share)*(not annualised) (0.38) 0.18(311.1%)2.53.54(29.4%)SHAREHOLDING13Ownership % (June 2025)•Number of Shareholders in Q1FY26 accounted to 16.64K •Promoter shareholding is free of any encumbrance (No change in FY25 and Q1FY26)Traded Volume (In K) BSE+NSEPercentage figures rounded off to show whole numbers33%12%8%42%5%PromoterHNIBody CorporatesOther Public ShareholdingNRI & Foreign Individuals14,09326,59318,43511,31314,1045,734Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY2614Investor Relations Ms. Deepika SharmaGo India Advisorsdeepika@goindiaadvisors.comM:+91 8451029510Ms. Priya Sen Go India Advisorspriya@goindiaadvisors.com M : +91 8334841047Company ContactAddressSadoday Gyan (Ground Floor), Opposite NADT, Nelson Square, Nagpur, Maharashtra 440013Mr. Zain DaudZim Laboratories Limitedzain.daud@zimlab.in M:+91 9022434631Ms. Sheetal KhandujaGo India Advisorssheetal@GoIndiaAdvisors.comM:+91 97693 64166www.zimlab.in+91 712 2981960